Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.
Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA.
Vaccine. 2022 Nov 2;40(46):6649-6657. doi: 10.1016/j.vaccine.2022.09.063. Epub 2022 Sep 28.
Vaccine hesitancy in the wake of the COVID-19 pandemic is a major public health concern in the US. Cancer patients are especially vulnerable to adverse COVID-19 outcomes and require targeted prevention efforts against COVID-19.
We used longitudinal survey data from patients seen at Moffitt Cancer Center to identify attitudes, beliefs, and sociodemographic factors associated with COVID-19 vaccination acceptance among cancer patients. Patients with confirmed invasive cancer diagnosis through Cancer Registry data were asked about vaccine acceptance through the question "Now that a COVID-19 vaccine is available, are you likely to get it?" and dichotomized into high accepters (already received it, would get it when available) and low accepters (waiting for a doctor to recommend it, waiting until more people received it, not likely to get it).
Most patients (86.8% of 5,814) were high accepters of the COVID-19 vaccine. High accepters had more confidence in the effectiveness and safety of the vaccine than low accepters. Multivariable logistic regression showed older individuals (70-89 vs.18-49: OR:2.57, 95% CI:1.33-4.86), those with greater perceived severity of COVID-19 infection (very serious vs. not at all serious: OR:2.55, 95% CI:1.76-3.70), practicing more risk mitigation behaviors (per one standard deviation OR:1.75, 95% CI:1.57-1.95), and history of receiving the flu shot versus not (OR:6.56, 95% CI:5.25-8.20) had higher odds of vaccine acceptance. Individuals living with more than one other person (vs. alone: OR: 0.53, 95% CI: 0.35, 0.79) and those who were more socioeconomically disadvantaged (per 10 percentile points: OR: 0.89, 95 %CI: 0.85, 0.93) had lower odds of reporting vaccine acceptance.
Most patients with cancer have or would receive the COVID-19 vaccine. Those who are less likely to accept the vaccine have more concerns regarding effectiveness and side effects, are younger, more socioeconomically disadvantaged, and have lower perceptions of COVID-19 severity.
在 COVID-19 大流行之后，疫苗犹豫成为美国主要的公共卫生关注点。癌症患者尤其容易受到 COVID-19 不良后果的影响，因此需要针对 COVID-19 采取预防措施。
我们使用 Moffitt 癌症中心患者的纵向调查数据，确定了与癌症患者对 COVID-19 疫苗接种接受程度相关的态度、信念和社会人口因素。通过癌症登记数据确诊患有侵袭性癌症的患者被问及疫苗接种接受程度，问题是“现在有 COVID-19 疫苗了，您是否有可能接种？”，并分为高接种者（已经接种，有疫苗时会接种）和低接种者（等待医生推荐，等待更多人接种，不太可能接种）。
大多数患者（5814 名患者中的 86.8%）是 COVID-19 疫苗的高接种者。高接种者比低接种者对疫苗的有效性和安全性更有信心。多变量逻辑回归显示，年龄较大的个体（70-89 岁与 18-49 岁：比值比：2.57，95%置信区间：1.33-4.86）、认为 COVID-19 感染严重程度更高的个体（非常严重与一点也不严重：比值比：2.55，95%置信区间：1.76-3.70）、采取更多风险缓解行为的个体（每一个标准差：比值比：1.75，95%置信区间：1.57-1.95）以及接种过流感疫苗的个体与未接种的个体（比值比：6.56，95%置信区间：5.25-8.20）更有可能接受疫苗接种。与独居者相比，与他人同住的人数超过一人的个体（比值比：0.53，95%置信区间：0.35-0.79）以及社会经济地位较低的个体（每 10 个百分点：比值比：0.89，95%CI：0.85-0.93）报告接种疫苗的可能性较低。
大多数癌症患者已经或将会接种 COVID-19 疫苗。那些不太可能接受疫苗的人对疫苗的有效性和副作用更为担忧，他们更年轻，社会经济地位较低，对 COVID-19 的严重程度认识较低。
